Ann: Race releases cardioprotection market potential data, page-186

I will do a write up soon, unfortunately couldn’t fully elaborate with references on the phone.

approach was looking at how the molecule is structured and working back from there. Also evaluated the mechanism of actions and pathways of the cardiotoxic drugs and overlay this with cardiotoxicity drivers, all seems to stack up nicely.

Also fits into the narrative as to why FTO is not needed for cardio protection, plus ticks the boxes across Dox, Carfilzomib and AC. In my view having it translate across other drugs provides a solid proof or work, as there is less margin for error.

Would be interested to get your thoughts once I post.